A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Ibrutinib (Primary) ; Carboplatin; Dexamethasone; Etoposide; Idarubicin; Ifosfamide; Rituximab; Vincristine
- Indications Non-Hodgkin's lymphoma
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 04 Aug 2017 Planned number of patients changed from 84 to 96.
- 10 Jun 2017 Biomarkers information updated
- 24 May 2017 Planned End Date changed from 31 Mar 2024 to 21 Mar 2024.